{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"HemeTalks: Conversations in Hematology Education","title":"TTP Today: Diagnosis, Management & Evolving Therapies","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/dbec8733\"></iframe>","width":"100%","height":180,"duration":1196,"description":"TTP is a hematologic emergency that demands immediate recognition and treatment to prevent fatal outcomes. In this HemeTalks episode, Dr. Yazan Abou-Ismail and Dr. Kolton Smith discuss the diagnostic hallmarks, therapeutic advances, and follow-up strategies for patients with TTP.\nThrough the lens of a clinical case, they explore the impact of caplacizumab, the importance of ADAMTS13 testing, and how to differentiate TTP from other TMAs. Tune in for practical insights that every hematologist and frontline provider should know.\nLearning Objectives:\nRecognize clinical and laboratory features indicative of TTP.\nUnderstand the evolving treatment landscape, including the role of caplacizumab.\nApply principles for acute and chronic management of both congenital and acquired TTP.\nClinical Pearls:\nAlways consider iTTP diagnosis in any patient with findings of thrombotic microangiopathy, as early recognition is critical.\nWhen iTTP is suspected, it is essential to start empiric therapy immediately—untreated disease carries a high mortality risk.\nMonitor closely for disease exacerbation or relapse even after initial clinical response is achieved.","thumbnail_url":"https://img.transistorcdn.com/ybjl9FP0yIIoAR9OW4-QMCeW4qWmBKc92wL1zHiuRRM/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYzM1/NDgwODVmNTJhYTU0/M2VjOGNiMjVlNzlk/NWI3MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}